nach oben

Tumor Biology

Erschienen in:

01.06.2014 | Research Article

Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis

verfasst von: Xuelei Ma, Zhilan Xiao, Xiaojun Li, Fengtian Wang, Jing Zhang, Rubai Zhou, Junbo Wang, Lei Liu

Erschienen in: Tumor Biology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) displayed their roles in prognosis prediction in prostate cancer. The objective of the present study was to conduct a systematic review and meta-analysis of published literature while investigating the correlation between survival outcome and CTCs or DTCs counts in patients with prostate cancer. Relevant literature was searched in Pubmed and Embase. Survival data of included study were extracted. Forrest plots were used to estimate the effect of CTCs/DTCs on the survival of patients. Publication bias was evaluated using Begg’s test. The estimated HRs and 95 % confidence interval for the effect of CTCs/DTCs on overall survival (OS) and biochemical relapse-free survival (bRFS) or disease-free survival (DFS) were 2.43 [2.07, 2.86] (p < 0.00001) and 2.15 [1.69, 2.73] (p < 0.00001), respectively. Subgroup analysis revealed that CTCs were also relevant to poor prognosis (hazard ratio (HR) 2.43 [2.05, 2.89] for OS, HR 2.46 [2.08, 2.90] for bRFS/DFS). A similar result was yielded in DTCs (1.47 [1.21, 1.80] for DFS). CTCs/DTCs could also predict poor OS in metastatic prostate cancer (2.37 [1.99, 2.82], p < 0.00001) and in localized stage (HR 1.84 [1.47, 2.28], p < 0.00001). In addition, CTCs/DTCs detected by different methods, especially by CellSearch system (HR for OS 2.36 [1.95, 2.85] and HR for bRFS/DFS 2.53 [1.66, 3.85]), were relevant to poor prognosis. Available evidence supported the notion of the strong prognostic value of CTCs. CTCs are promising biomarkers that are clinically implemented in the therapeutic decision-making process in patients with prostate cancer.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed

Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389–96.PubMedCentralCrossRefPubMed

Cooner WH, Mosley BR, Rutherford Jr CL, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1144–6.

Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605–12.CrossRefPubMed

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. Eau guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.CrossRefPubMed

Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146–9.

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793–802.CrossRefPubMed

Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012;18:5701–10.CrossRefPubMed

ᅟCohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26:3213–3221.

10.

Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:1556–63.CrossRef

11.

Olmos D, Arkenau H, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol. 2009;20:27–33.CrossRefPubMed

12.

Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996;347:649–53.CrossRefPubMed

13.

Pierga J-Y, Bidard F-C, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:7004–10.CrossRef

14.

Rack BK, Schindlbeck C, Schneeweiss A, Hilfrich J, Lorenz R, Beckmann MW, Pantel K, Lichtenegger W, Sommer HL, Janni WJ. Prognostic relevance of circulating tumor cells (CTCS) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the german success-trial. 2008.

15.

Ghossein R, Rosai J, Scher H, Seiden M. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic. Urology. 1997;4295:100–5.CrossRef

16.

Goodman OB, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomark Prev. 2009;18:1904–13.CrossRef

17.

Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232–7.CrossRefPubMed

18.

Hara N, Kasahara T, Kawasaki T. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res. 2002;8:1794–9.PubMed

19.

Joung JAEY, Cho KSU, Kim JEUN, Seo HOK, Chung J, Park WSEO, et al. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J Surg Oncol. 2010;101:145–8.PubMed

20.

Lembessis P, Msaouel P. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts. Clin Chem Lab Med. 2007;45:1488–94.CrossRefPubMed

21.

Moreno J, Miller M, Gross S, Allard W. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005;65:713–8.CrossRefPubMed

22.

Okegawa T, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic. J Urol. 2008;180:1342–7.CrossRefPubMed

23.

Okegawa T, Nutahara K, Higashihara E. Original article: clinical investigation association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory. Int J Urol. 2010;17:466–75.CrossRefPubMed

24.

Okegawa T, Nutahara K, Higashihara E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol. 2009;181:1091–7.CrossRefPubMed

25.

Olsson CA, Vries GMDE, Raffo AJ, Benson MC, Otoole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol. 1996;155:1557–62.CrossRefPubMed

26.

Scher HI, Jia X, Bono JSD, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer : a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233–9.PubMedCentralCrossRefPubMed

27.

Strijbos MH, Gratama JW, Schmitz PIM, Rao C, Onstenk W, Doyle GV, et al. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer. 2010;46:2027–35.CrossRefPubMed

28.

Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thüroff JW, et al. Urokinase-plasminogen-activator receptor expression in desseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. Int Br J Urol. 2008;104:29–34.CrossRef

29.

Weckermann D, Polzer B, Ragg T, Blana A, Bertz S, Harzmann R, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009;27:1549–56.CrossRefPubMed

30.

Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kreß V, et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013;139:755–63.CrossRefPubMed

31.

Resel Folkersma L, San José Manso L, Galante Romo I, Moreno Sierra J, Olivier Gómez C. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology. 2012;80:1328–32.CrossRefPubMed

32.

Wood Jr DP, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15:3451–7.

33.

Berg A, Berner A, Lilleby W, Bruland ØS, Foss SD. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer. 2007;120:1603–9.CrossRefPubMed

34.

Gewanter R, Katz A, Olsson C. RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. Urology. 2003;4295:967–71.CrossRef

35.

Mejean A, Vona G, Naplas B. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol. 2000;163:2022–9.CrossRefPubMed

36.

Oefelein M, Ignatoff J. Clinical and molecular followup after radical retropubic prostatectomy. J Urol. 1999;162:307–10.CrossRefPubMed

37.

Shariat S, Gottenger E, Nguyen C. Reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002;62:5974–9.PubMed

38.

Tierney JF, Stewart L, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralCrossRefPubMed

39.

Bianco Jr FJ, Powell IJ, Cher ML, Wood Jr DP. Presence of circulating prostate cancer cells in African American males adversely affects survival. Urologic Oncology: Seminars and Original Investigations, Elsevier, 2002, 7, pp 147–152.

40.

DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary Clinical Trials. 2007;28:105–14.CrossRefPubMed

41.

Easterbrook PJ, Gopalan R, Berlin JA, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72.CrossRefPubMed

42.

Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15:677–83.PubMedCentralCrossRefPubMed

43.

Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:2023–9.CrossRefPubMed

44.

Doyen J, Alix-Panabières C, Hofman P, Parks SK, Chamorey E, Naman H, et al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Critical Rev Oncol/Hematol. 2012;81:241–56.CrossRef

45.

Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–9.PubMedCentralCrossRefPubMed

46.

Groot Koerkamp B, Rahbari NN, Buchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Annals Surg Oncol. 2013;20:2156–65.CrossRef

47.

Ma X-L, Xiao Z-L, Liu L, Liu X-X, Nie W, Li P, et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev. 2012;13:1137–44.CrossRefPubMed

48.

Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? Prognostic variables in node-negative and node-positive breast cancer, Breast Cancer Res Tr. Kluwer Academic Publishers, Netherlands, 1998, 395–409.

49.

Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329–40.CrossRefPubMed

50.

Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer cell. 2013;23:573–81.PubMedCentralCrossRefPubMed

51.

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–4.PubMedCentralCrossRefPubMed

52.

Hou J-M, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525–32.CrossRefPubMed

Titel: Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis
verfasst von: Xuelei Ma
Zhilan Xiao
Xiaojun Li
Fengtian Wang
Jing Zhang
Rubai Zhou
Junbo Wang
Lei Liu
Publikationsdatum: 01.06.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 6/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1731-5

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma

Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460

Expression of RUNX3 and β-catenin in the carcinogenesis of sporadic colorectal tubular adenoma

Association of genetic variants of xenobiotic and estrogen metabolism pathway (CYP1A1 and CYP1B1) with gallbladder cancer susceptibility

Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies

Molecular mechanism of inhibitory effects of C-phycocyanin combined with all-trans-retinoic acid on the growth of HeLa cells in vitro

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie